Sugi Predict

Sugi Predict / Compounds / Phthalimide

Phthalimide

Phthalimide

SCHEMBL3914569

CCCC[P+](CCCC)(CCCC)CCCC.O=C1[N-]C(=O)c2ccccc21

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DNM1 Q05193 2/20 0.40
▸ ALDH1A1 P00352 4/20 0.39
▸ PTPN1 P18031 1/20 0.39
▸ APAF1 O14727 1/20 0.39
▸ SOAT1 P35610 9/20 0.38
▸ S100A4 P26447 1/20 0.38
▸ BDKRB2 P30411 1/20 0.38
▸ NPC1 O15118 3/20 0.37
▸ MAPT P10636 3/20 0.37
▸ RAB9A P51151 3/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ MITF O75030 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ RECQL P46063 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrabuthylammonium SCHEMBL8967565 0.78 SLC22A1 (0.44) ALDH1A1PTPN1SOAT1SMN1; SMN2
Phthalimide SCHEMBL7521029 0.72 KMT2A (0.47) ALDH1A1APAF1S100A4NPC1MAPT
Phthalimide SCHEMBL543799 0.72 KMT2A (0.47) ALDH1A1APAF1S100A4NPC1MAPT
Phthalimide SCHEMBL4948701 0.72 KMT2A (0.47) ALDH1A1APAF1S100A4NPC1MAPT
Phthalimide SCHEMBL443472 0.72 KMT2A (0.47) ALDH1A1APAF1S100A4NPC1MAPT
Phthalimide SCHEMBL9137612 0.72 KMT2A (0.47) ALDH1A1APAF1S100A4NPC1MAPT
Phthalimide SCHEMBL9230 0.72 KMT2A (0.47) ALDH1A1APAF1S100A4NPC1MAPT
Phthalimide SCHEMBL30464238 0.72 KMT2A (0.47) ALDH1A1APAF1S100A4NPC1MAPT
Phthalimide SCHEMBL228978 0.72 KMT2A (0.47) ALDH1A1APAF1S100A4NPC1MAPT
Phthalimide SCHEMBL5742515 0.72 KMT2A (0.47) ALDH1A1APAF1S100A4NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112812287-A Method for preparing polycarbonate by ionic liquid catalysis 中国科学院过程工程研究所 2021-05-18 — — CN disclosed
US-7488818-B2 Method for producing 1,4-diphenyl azetidinone derivatives SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-02-10 — — US disclosed
EP-1756049-B1 METHOD FOR PRODUCING 1,4-DIPHENYL AZETIDINONE DERIVATIVES SANOFI AVENTIS DEUTSCHLAND (DE) 2007-10-31 — — EP disclosed
US-20070149776-A1 METHOD FOR PRODUCING 1,4-DIPHENYL AZETIDINONE DERIVATIVES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-28 — — US disclosed
EP-1756049-A1 METHOD FOR PRODUCING 1,4-DIPHENYL AZETIDINONE DERIVATIVES Sanofi-Aventis Deutschland GmbH (DE) 2007-02-28 — — EP disclosed
WO-2005113496-A1 METHOD FOR PRODUCING 1,4-DIPHENYL AZETIDINONE DERIVATIVES SANOFI-AVENTIS DEUTSCHLAND GMBH (US) 2005-12-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149776-A1 METHOD FOR PRODUCING 1,4-DIPHENYL AZETIDINONE DERIVATIVES CYP46A1, CYP51A1, APOB DNM1 1303/4885ALDH1A1 235/4885PTPN1 3033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.